The RATIONALE-306 study, a global trial involving both East Asian and Western patients, evaluates the efficacy of combining the investigator’s choice doublet chemotherapy with or without tislelizumab, a PD-L1 antibody also possessing ADC properties. Notably, this was a first-line treatment

The CodeBreak 300 is the first phase 3 trial including chemorefractory patients with KRAS G12C mutation, randomized into two treatment arms: sotorasib dosed at 960 mg or 240 mg once daily, combined with panitumumab IV every two weeks. At the

Depending on the molecular profile of the tumour different treatment options for metastatic colorectal cancer (mCRC) emerge. The MOUNTAINEER-02 trial presents results of combining tucatinib (TUC) with trastuzumab (Tras) in a subgroup of HER2+, RAS WT mCRC patients. HER2 positivity

The upcoming episode for WND in GI cancer will focus on the groundbreaking CheckMate 8HW trial in MSI-H/dMMR metastatic colorectal cancer patients. This phase 3 trial involved randomization between double immunotherapy with NIVO and IPI versus NIVO alone or the

Prof Eric Van Cutsen from University Hospitals Leuven is invited by Prof Marc Van den Eynde from Cliniques Universitaires Saint Luc to shed light on the KEYNOTE-585 and the MATTERHORN study. These two important studies in gastric cancer investigate the

In the KEYNOTE 811 study, a randomised, double-blind phase 3 trial, the combination of trastuzumab plus pembrolizumab was investigated in patients with HER2-positive metastatic gastroesophageal junction or gastric cancer in the first-line treatment. The trial included patients treated with chemotherapy

The absence of efficacious interventions for advanced, chemotherapy-refractory colorectal cancer necessitates the exploration of novel therapeutic agents. In this context, fruquintinib was investigated in a phase 3 study involving heavily pretreated patients who had experienced progression on or intolerance to

The SUNLIGHT trial undertook a comparative investigation of metastatic colorectal cancer treatment, evaluating the classical trifluridine–tipiracil (FTD–TPI) regimen with or without the addition of bevacizumab, a VEGF-inhibitor. Enrolled patients had previously undergone one or two discontinued chemotherapy regimens due to

In metastatic gastric cancer patients, approximately one-third exhibit positivity for CLDN18.2, an antigen also identified in other malignancies such as pancreatic cancer. Zolbetuximab, a novel monoclonal antibody drug, selectively targets CLDN18.2. Two concurrent studies were conducted to investigate this agent’s

The KEYNOTE-859 trial explores the integration of immune therapy with chemotherapy in the first-line management of metastatic gastric cancer. Employing a double-blind phase 3 design, patients were randomized to receive IV with 200 mg pembrolizumab or placebo every 3 weeks,

The LEAP-017 study represents an exploration into the application of immunotherapy for refractory metastatic colorectal cancer, a domain where therapeutic options are limited. This randomised phase 3 trial, presented at the ESMO World Congress in Barcelona, aimed to elucidate the

The NAPOLI-3 study emerges as a pivotal contribution to the field of metastatic pancreatic cancer. This phase 3 study undertakes a comparative assessment of two contemporary regimens for first-line treatment of pancreatic cancer. One arm of the study administered NALIRIFOX,